Treatment can be delayed for low-risk prostate cancer patients until warranted by disease progression, according to an NIH panel. Defining low-risk prostate cancer as prostate-specific antigen levels of less than 10 ng/mL and a Gleason score of 6 or less, the panel estimated that more than 100,000 men diagnosed with the cancer each year would not require immediate therapy, but only active monitoring.

Full Story:

Related Summaries